Study of Oxybutynin Extended-Release Tablets to Help Early Urinary Control After Robotic Prostate Surgery for Localized Prostate Cancer

What this Trial Is About

Researchers are evaluating whether oxybutynin chloride extended-release tablets can improve early continence recovery after robot-assisted radical prostatectomy RARP in patients with localized prostate cancer. This double-blind, randomized, placebo-controlled study aims to compare oxybutynin chloride with a placebo and identify factors that predict continence recovery. Participants are randomly assigned to receive either oxybutynin chloride extended-release tablets at a dose of 10 mg per day two 5 mg tablets or placebo tablets that look identical. Treatment lasts from 1 to 3 months or until participants regain complete continence, defined as needing no urinary pads and less than one episode of incontinence per week. During the study, participants complete surveys measuring urinary symptoms, erectile function, and incontinence at multiple time points before and after surgery, including up to 12 months post-surgery. Researchers will monitor adverse events and medication use, assessing continence outcomes and treatment safety over the study period.

Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial